Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 1 Monat 2 Wochen
@MorphoSys
MOR208 is now tafasitamab!
Tafasitamab - our proprietary Fc-enhanced antibody targeting CD19 in late stage clinica… https://t.co/8xy5KL3fkR
vor 6 Monate 2 Wochen
@MorphoSys
Great News! MorphoSys’ licensee Janssen reported data from the phase 3 head-to-head ECLIPSE study with Tremfya®(gus… https://t.co/z7kHQKPAU3
vor 7 Monate 15 Stunden
@MorphoSys
Great news for Japanese patients: Tremfya® now approved for palmoplantar pustulosis in Japan. Congrats to our licen… https://t.co/03l5oPE7IR
vor 7 Monate 6 Tage
@MorphoSys
Phase 2 study with guselkumab started by our licensee Janssen in chronic skin disease hidradenitis suppurativa (HS)… https://t.co/opXoqzNPvH
vor 7 Monate 1 Woche
@MorphoSys
Triumph for Tremfya® (guselkumab): Awarded as the “most innovative product” in dermatology in the German Pharma Tre… https://t.co/s2T0gGJOJj
vor 7 Monate 2 Wochen
@MorphoSys
MorphoSys Management Team will host conference call and webcast to present the third quarter results 2018. See the… https://t.co/uo8xamUzIa
vor 7 Monate 3 Wochen
@MorphoSys
MorphoSys to present data on MOR208 (L-MIND, COSMOS) & MOR202 at #ASH18, abstracts now online https://t.co/7qJfYzVTw0 $MPSYF
vor 10 Monate 3 Wochen
@MorphoSys
MorphoSys second quarter 2018, with further advanced
pipeline and a newly established U.S. footprint
https://t.co/FwtqTxnNLX $MPSYF
vor 11 Monate 4 Tage
@MorphoSys
MorphoSys appointed Jennifer Herron as President of
MorphoSys US Inc. and Executive Vice President, Global Commerci… https://t.co/seSxiqMNt8
vor 11 Monate 1 Woche
@MorphoSys
MorphoSys increases financial guidance 2018 due to license agreement for
MOR106, currently developed in atopic derm… https://t.co/7L9ZSrMs3L
Medien und Investoren
Corporate Communications und Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
E-Mail Kontakt